BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 21450986)

  • 1. Risk-adapted management of differentiated thyroid cancer assessed by a sensitive measurement of basal serum thyroglobulin.
    Malandrino P; Latina A; Marescalco S; Spadaro A; Regalbuto C; Fulco RA; Scollo C; Vigneri R; Pellegriti G
    J Clin Endocrinol Metab; 2011 Jun; 96(6):1703-9. PubMed ID: 21450986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Highly sensitive serum thyroglobulin and circulating thyroglobulin mRNA evaluations in the management of patients with differentiated thyroid cancer in apparent remission.
    Fugazzola L; Mihalich A; Persani L; Cerutti N; Reina M; Bonomi M; Ponti E; Mannavola D; Giammona E; Vannucchi G; di Blasio AM; Beck-Peccoz P
    J Clin Endocrinol Metab; 2002 Jul; 87(7):3201-8. PubMed ID: 12107225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical relevance of highly sensitive Tg assay in monitoring patients treated for differentiated thyroid cancer.
    Iervasi A; Iervasi G; Ferdeghini M; Solimeo C; Bottoni A; Rossi L; Colato C; Zucchelli GC
    Clin Endocrinol (Oxf); 2007 Sep; 67(3):434-41. PubMed ID: 17555505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Three-week thyroxine withdrawal thyroglobulin stimulation screening test to detect low-risk residual/recurrent well-differentiated thyroid carcinoma.
    Golger A; Fridman TR; Eski S; Witterick IJ; Freeman JL; Walfish PG
    J Endocrinol Invest; 2003 Oct; 26(10):1023-31. PubMed ID: 14759077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thyroglobulin monitoring after treatment of well-differentiated thyroid cancer.
    Hamy A; Mirallié E; Bennouna J; Resche I; Drefty C; Johnstone M; Visset J
    Eur J Surg Oncol; 2004 Aug; 30(6):681-5. PubMed ID: 15256244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unstimulated highly sensitive thyroglobulin in follow-up of differentiated thyroid cancer patients: a meta-analysis.
    Giovanella L; Treglia G; Sadeghi R; Trimboli P; Ceriani L; Verburg FA
    J Clin Endocrinol Metab; 2014 Feb; 99(2):440-7. PubMed ID: 24285679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low specificity of blood thyroglobulin messenger ribonucleic acid assay prevents its use in the follow-up of differentiated thyroid cancer patients.
    Elisei R; Vivaldi A; Agate L; Molinaro E; Nencetti C; Grasso L; Pinchera A; Pacini F
    J Clin Endocrinol Metab; 2004 Jan; 89(1):33-9. PubMed ID: 14715824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monitoring differentiated thyroid cancer patients with negative serum thyroglobulin. Diagnostic implication of TSH-stimulated antithyroglobulin antibody.
    Nam HY; Paeng JC; Chung JK; Kang KW; Cheon GJ; Kim Y; Park DJ; Park YJ; Min HS; Lee DS
    Nuklearmedizin; 2014; 53(2):32-8. PubMed ID: 24276613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. On-levothyroxine measurement of thyroglobulin is not a reliable test for the follow-up of patients at high risk for remnant/recurrent differentiated thyroid carcinoma.
    Gholamrezanezhad A; Saghari M; Mirpour S; Beiki D; Tarbiat A; Javan S; Abdollahzadeh J
    Endokrynol Pol; 2007; 58(2):100-4. PubMed ID: 17578824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preoperative undetectable serum thyroglobulin in differentiated thyroid carcinoma: incidence, causes and management strategy.
    Giovanella L; Ceriani L; Ghelfo A; Maffioli M; Keller F
    Clin Endocrinol (Oxf); 2007 Oct; 67(4):547-51. PubMed ID: 17561976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Follow-up of differentiated thyroid carcinoma.
    Pagano L; Klain M; Pulcrano M; Angellotti G; Pasano F; Salvatore M; Lombardi G; Biondi B
    Minerva Endocrinol; 2004 Dec; 29(4):161-74. PubMed ID: 15765026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum Basal thyroglobulin measured by a second-generation assay correlates with the recombinant human thyrotropin-stimulated thyroglobulin response in patients treated for differentiated thyroid cancer.
    Spencer C; Fatemi S; Singer P; Nicoloff J; Lopresti J
    Thyroid; 2010 Jun; 20(6):587-95. PubMed ID: 20470203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Do thyroid cancer patients with basal undetectable Tg measured by current immunoassays require rhTSH testing?
    Díaz-Soto G; Puig-Domingo M; Martínez-Pino I; Martínez de Osaba MJ; Mora M; Rivera-Fillat F; Halperin I
    Exp Clin Endocrinol Diabetes; 2011 Jun; 119(6):348-52. PubMed ID: 21264807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum thyroglobulin measurements with a high sensitivity enzyme-linked immunosorbent assay: is there a clinical benefit in patients with differentiated thyroid carcinoma?
    Zöphel K; Wunderlich G; Smith BR
    Thyroid; 2003 Sep; 13(9):861-5. PubMed ID: 14588100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation?
    Mazzaferri EL; Kloos RT
    J Clin Endocrinol Metab; 2002 Apr; 87(4):1490-8. PubMed ID: 11932270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discordance in thyroglobulin measurements by radioimmunoassay and immunometric assay: a useful means of identifying thyroglobulin assay interference.
    Crane MS; Strachan MW; Toft AD; Beckett GJ
    Ann Clin Biochem; 2013 Sep; 50(Pt 5):421-32. PubMed ID: 23847033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Value of stimulated serum thyroglobulin levels for detecting persistent or recurrent differentiated thyroid cancer in high- and low-risk patients.
    Duren M; Siperstein AE; Shen W; Duh QY; Morita E; Clark OH
    Surgery; 1999 Jul; 126(1):13-9. PubMed ID: 10418587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of residual and recurrent differentiated thyroid carcinoma by serum thyroglobulin measurement.
    Spencer CA; LoPresti JS; Fatemi S; Nicoloff JT
    Thyroid; 1999 May; 9(5):435-41. PubMed ID: 10365673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High sensitive thyroglobulin assay on thyroxine therapy: can it avoid stimulation test in low and high risk differentiated thyroid carcinoma patients?
    Trimboli P; La Torre D; Ceriani L; Condorelli E; Laurenti O; Romanelli F; Ventura C; Signore A; Valabrega S; Giovanella L
    Horm Metab Res; 2013 Sep; 45(9):664-8. PubMed ID: 23720229
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unstimulated high sensitive thyroglobulin measurement predicts outcome of differentiated thyroid carcinoma.
    Giovanella L; Maffioli M; Ceriani L; De Palma D; Spriano G
    Clin Chem Lab Med; 2009; 47(8):1001-4. PubMed ID: 19589104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.